Dr. Weiss Discusses Current Clinical Trials in Head and Neck Cancer

Jared Weiss, MD
Published: Wednesday, Jul 19, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Currently, Weiss is involved in a clinical trial incorporating immunotherapy with radiation—which has investigators from various cancer centers hopeful that this regimen could be a replacement for cisplatin, with a higher cure rate and less toxicities.

There is also a study that combines durvalumab (Imfinzi) carboplatin and nab-paclitaxel as induction therapy prior to surgery for hard-to-treat patients.
 
SELECTED
LANGUAGE


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Currently, Weiss is involved in a clinical trial incorporating immunotherapy with radiation—which has investigators from various cancer centers hopeful that this regimen could be a replacement for cisplatin, with a higher cure rate and less toxicities.

There is also a study that combines durvalumab (Imfinzi) carboplatin and nab-paclitaxel as induction therapy prior to surgery for hard-to-treat patients.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x